comparemela.com

Latest Breaking News On - Biocryst pharmaceuticals chart - Page 1 : comparemela.com

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) Treatment

23.02.2024 - RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO (berotralstat) that showed patients who initiated ORLADEYO . Seite 1

United statesBryan arnoldJonathan bernsteinBernstein clinical research centerUniversity of cincinnatiBernstein allergy groupBernstein clinical researchRate reduction after beginningMultiple patientBiocryst pharmaceuticals chartIocryst pharmaceuticals kursIocryst pharmaceuticals aktie

BioCryst to Present at Upcoming Investor Conferences

21.02.2024 - RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2024 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the TD Cowen 44th Annual Health Care Conference in Boston on Wednesday, March 6, 2024, at .

United statesBiocryst pharmaceuticals incHealth care conferenceCryst pharmaceuticalsAnnual health care conferenceAnnual global healthcare conferenceBiocryst pharmaceuticals chartIocryst pharmaceuticals kursIocryst pharmaceuticals aktie

BioCryst Launches ORLADEYO (berotralstat) in Italy

19.02.2024 - RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended .

Charlie gayerBiocryst pharmaceuticals incItalian medicines agencyCryst pharmaceuticalsAgenzia italiana del farmacoBiocryst pharmaceuticals chartIocryst pharmaceuticals kursIocryst pharmaceuticals aktie

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02.02.2024 - RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2024 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to .

Biocryst pharmaceuticals incCryst pharmaceuticalsNasdaq listing ruleInducement equity incentive planBiocryst pharmaceuticals chartIocryst pharmaceuticals kursIocryst pharmaceuticals aktie

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside s Proprietary SCS Microinjector Seite 1

03.11.2023 - – SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space – – BioCryst to host R&D Day today at 1:00 pm ET – ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) - . Seite 1

Jon stonehouseGeorge lasezkayClearside biomedical incBiocryst pharmaceuticals incCryst pharmaceuticalsClearside biomedicalBiocryst pharmaceuticals chartIocryst pharmaceuticals kursIocryst pharmaceuticals aktie

vimarsana © 2020. All Rights Reserved.